August 04, 2020
4 min watch
Save
VIDEO: Novartis takes proactive approach to address Beovu concerns
In this video, Patrick Mooney, Beovu Coalition lead, discusses the company’s proactive approach to address safety concerns associated with Beovu treatment for wet age-related macular degeneration.
Novartis has created an independent safety review committee, initiated a safety label update for Beovu (brolucizumab-dbll) globally and commissioned a global panel of 100 medical experts to answer key questions relating to the occurrence of retinal vasculitis or retinal vascular occlusion associated with treatment.
Editor’s Note, Aug. 6, 2020: In this video, Patrick Mooney’s disclosure should include that he is Beovu Coalition lead.